Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation

British Journal of Pharmacology

Volumn 160, Issue 3, 2010, Pages 615-626

  Makwana, R ^a   Molleman, A ^b   Parsons, Me ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Cannabinoid; Cannabinoid receptor agonists; Cannabinoid receptor antagonists; Cannabinoid receptor inverse agonists; Endocannabinoid tone; Fatty acid amide hydrolase; Inverse agonism; Myenteric plexus; Small intestine

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (1 METHANESULPHONYLAMINO 4 HEXYN 6 YL) 6A,7,10,10A TETRAHYDRO 6,6,9 TRIMETHYL 6H DIBENZO[B,D]PYRAN; ANANDAMIDE; BENZYLSULFONYL FLUORIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; O 2050; PHYSOSTIGMINE; SEROTONIN; UNCLASSIFIED DRUG; (6AR,10AR)-3-(1-METHANSULFONYLAMINO-4-HEXYN-6-YL)6A,7,10,10A-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO(B,D)PYRAN; AMIDASE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID; CANNABINOID RECEPTOR AFFECTING AGENT; DRONABINOL; FATTY-ACID AMIDE HYDROLASE; N-(2-METHYL-3-HYDROXYPHENYL)-5,8,11,14-EICOSATETRAENAMIDE; PIPERIDINE DERIVATIVE; PYRAN DERIVATIVE; PYRAZOLE DERIVATIVE; RIMONABANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; ELECTRIC FIELD; GUINEA PIG; HYDROLYSIS; ILEUM; INVERSE AGONISM; MALE; MUSCLE CONTRACTION; MYENTERIC PLEXUS; NONHUMAN; PRIORITY JOURNAL; RAT; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; CANNABINOID RECEPTOR MODULATORS; CANNABINOIDS; DRONABINOL; DRUG INVERSE AGONISM; GUINEA PIGS; ILEUM; MUSCLE CONTRACTION; MYENTERIC PLEXUS; PIPERIDINES; PYRANS; PYRAZOLES; RATS; RECEPTOR, CANNABINOID, CB1;

EID: 77952586508     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00717.x     Document Type: Article

References (45)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels, 3rd edition. Br J Pharmacol 153 : S1 S209.
2. Bisogno T, Melck D, De Petrocellis L, Bobrov MYu, Gretskaya NM, Bezuglov VV et al 1998). Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun 248 : 515 522.
3. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M et al 1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272 : 22330 22339.
4. Capasso R, Matias I, Lutz B, Borrelli F, Capasso F, Marsicano G et al 2005). Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 129 : 941 951.
5. Colombo G, Agabio R, Lobina C, Reali R, Gessa GL (1998). Cannabinoid modulation of intestinal propulsion in mice. Eur J Pharmacol 344 : 67 69.
6. Coutts AA, Pertwee RG (1997). Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol 121 : 1557 1566.
7. Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S (2002). Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 448 : 410 422.
8. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V (2000). Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 483 : 52 56.
9. Deutsch DG, Lin S, Hill WA, Morse KL, Salehani D, Arreaza G et al 1997). Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun 231 : 217 221.
10. Di Marzo V, Bifulco M, De Petrocellis L (2004). The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3 : 771 784.
11. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G et al 2005). Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313 : 352 358.
12. Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ et al 1998). LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 284 : 291 297.
13. Gatley SJ, Lan R, Pyatt B, Gifford AN, Volkow ND, Makriyannis A (1997). Binding of the non-classical cannabinoid CP 55,940 and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci 61 : PL191 PL197.
14. Guagnini F, Cogliati P, Mukenge S, Ferla G, Croci T (2006). Tolerance to cannabinoid response on the myenteric plexus of guinea-pig ileum and human small intestinal strips. Br J Pharmacol 148 : 1165 1173.
15. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al 2002). International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev 54 : 161 202.
16. Izzo AA, Mascolo N, Borrelli F, Capasso F (1999a). Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol 359 : 65 67.
17. Izzo AA, Mascolo N, Pinto L, Capasso R, Capasso F (1999b). The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol 384 : 37 42.
18. Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Iuvone T et al 2001). Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 134 : 563 570.
19. Izzo AA, Capasso F, Costagliola A, Bisogno T, Marsicano G, Ligresti A et al 2003). An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 125 : 765 774.
20. Katayama K, Ueda N, Kurahashi Y, Suzuki H, Yamamoto S, Kato I (1997). Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochim Biophys Acta 1347 : 212 218.
21. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A et al 2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9 : 76 81.
22. Kenakin TP, Onaran O (2002). The ligand paradox between affinity and efficacy: can you be there and not make a difference. Trends Pharmacol Sci 23 : 275 280.
23. 1 receptor. Eur J Pharmacol 334 : R1 R2.
24. Leff P (1995). The two-state model of receptor activation. Trends Pharmacol Sci 16 : 89 97.
25. Lynn AB, Herkenham M (1994). Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 268 : 1612 1623.
26. 2 receptors. Br J Pharmacol 124 : 619 622.
27. McVey D, Schmid P, Schmid H, Vigna S (2003). Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). J Pharmacol Exp Ther 304 : 713 722.
28. Makwana R, Molleman A, Parsons ME (2006). The receptors mediating the inhibitory effects of cannabinoids on the electrically stimulated rat isolated myenteric plexus longitudinal muscle preparation are dependent on the frequency of stimulation. Symposium on the cannabinoids. Burlington, Vermont, International Cannabinoid Research Society: page 56.
29. Makwana R, Molleman A, Parsons ME (2007). Is there an endogenous cannabinoid tone in the guinea-pig and rat isolated ileum myenteric plexus-longitudinal muscle? Proceedings of the British Pharmacological Society WWW document].URL http://www.pa2online.org/abstracts/Vol4Issue2abst094P.pdf.
30. 1 cannabinoid receptors. Br J Pharmacol 134 : 161 167.
31. Martin BR, Stevenson LA, Pertwee RG, Breivogel CS, Williams W, Mahadevan A et al 2002). Agonists and silent antagonists in a series of cannabinoid sulfonamides. Symposium on the cannabinoids. Burlington, Vermont, International Cannabinoid Research Society, Page 2.
32. Mascolo N, Izzo AA, Ligresti A, Costagliola A, Pinto L, Cascio MG et al 2002). The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J 16 : 1973 1975.
33. Paton WDM, Zar AM (1968). The origin of acetylcholine released from guinea-pig intestine and longitudinal muscle strips. J Physiol 194 : 13 33.
34. Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A (1995). AM 630, a competitive cannabinoid receptor antagonist. Life Sci 56 : 1949 1955.
35. Pertwee RG (2005). Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76 : 1307 1324.
36. 1 receptors in mouse urinary bladder. Br J Pharmacol 118 : 2053 2058.
37. Pertwee RG, Fernando SR, Nash JE, Coutts AA (1996). Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br J Pharmacol 118 : 2199 2205.
38. Pinto L, Izzo AA, Cascio MG, Bisogno T, Hospodar-Scott K, Brown DR et al 2002). Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123 : 227 2234.
39. Randall MD, Alexander SPH, Bennett T, Boyd EA, Fry JR, Gardiner SM et al 1996). An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Commun 229 : 114 120.
40. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C et al 1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350 : 240 244.
41. x and competitive drug antagonism. Br J Pharmacol 4 : 277 280.
42. van der Stelt M, Di Marzo V (2004). Metabolic fate of endocannabinoids. Curr Neuropharm 2 : 37 48.
43. Ueda N, Puffenbarger RA, Yamamoto S, Deutsch DG (2000). The fatty acid amide hydrolase (FAAH). Chem Phys Lipids 108 1-2 107 121.
44. Valenti M, Gianfrani C, Mukenge S, Scaglione G, D'Argenio G, Ferla G et al 2005). Involvement of endocannabinoids and palmitoylethanolamide in intestinal disorders with inflammatory complications: human studies. Symposium on the cannabinoids. Burlington, Vermont, International Cannabinoid Research Society: page 158.
45. White R, Hiley CR (1998). The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br J Pharmacol 125 : 689 696.